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Bipolar illnessCognitive impairment is an important predictor of functional outcome inpatientswith schizophrenia, yet its neu-
robiology is still incompletely understood. Neuropathological evidence of impaired synaptic connectivity and
NMDA receptor-dependent transmission in superior temporal cortex motivated us to explore the correlation
of in vivo mismatch negativity (MMN) with cognitive status in patients with schizophrenia. MMN elicited in a
roving stimulus paradigm displayed a response proportional to the number of stimulus repetitions (memory
trace effect). Preliminary evidence in patients with chronic schizophrenia suggests that attenuation of this
MMN memory trace effect was correlated with the degree of neuropsychological memory dysfunction. Here
we present data from a larger conﬁrmatory study in patients with schizophrenia, bipolar disorder, probable
Alzheimer's disease and healthy controls. We observed that the diminution of the MMN memory trace effect
and its correlationwithmemory impairmentwas only found in the schizophrenia group. Recent pharmacological
studies using the roving paradigm suggest that attenuation of theMMN trace effect can be understood as abnor-
mal modulation of NMDA receptor-dependent plasticity. We suggest that the convergence of the previously
identiﬁed synaptic pathology in supragranular cortical layers with the intracortical locus of MMN generation ac-
counts for the remarkable robustness of MMN impairments in schizophrenia. We further speculate that this
layer-speciﬁc synaptic pathology identiﬁed in supragranular neurons plays a pivotal computational role, by
weakening the encoding and propagation of prediction errors to higher cortical modules. According to predictive
coding theory such breakdown will have grave implications not only for perception, but also for higher-order
cognition and may thus account for the MMN–cognition correlations observed here. Finally, MMN is a sensitive
and speciﬁc biomarker for detecting the early prodromal phase of schizophrenia and is well suited for the explo-
ration of novel cognition-enhancing agents in humans.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
1.1. Deﬁning the microcircuit
Research into mismatch negativity (MMN) represents a successful
translational application of cognitive electrophysiology to neuropsychi-
atric disorders. This is particularly true for research into schizophrenia,
a disorder which so far has escaped a comprehensive descriptionar disorder; MMN, mismatch
lth, 30 Guilford Street, London
x: +44 207 905 2161.
. This is an open access article underof its underlyingpathophysiology.MMNdeﬁcits in patientswith schizo-
phrenia have been replicated many times since the original observa-
tions by Shelley et al. (1991), making MMN one of the most robust
biological markers of this complex disorder (Umbricht and Krljes,
2005). Amodern formulation suggests that schizophrenia can be under-
stood ‘as a complex genetic disorder of cortical microcircuits’ (Harrison
andWeinberger, 2005)where risk genes (eachwith relatively small im-
pact) converge functionally on synaptic plasticity and stabilisation of
microcircuitry, especially implicating NMDA receptor-mediated gluta-
mate transmission.
In this paper we review progress made in applying MMN to charac-
terise one important aspect of schizophrenia which until recently has
not received sufﬁcient attention — the cognitive impairment associated
with schizophrenia (CIAS, reviewed by Michalopoulou et al., 2013),
which can manifest separately from the more ﬂorid symptoms ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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addition, we present empirical data which support the hypothesis
that the cortical microcircuits generating MMN index illness-speciﬁc
dysfunction of (NMDA receptor-dependent) auditory cortical plasticity,
which extends to higher-order networks that collectively give rise to
the cognitive phenotype of schizophrenia.
1.2. MMN and cognitive impairment in schizophrenia
Since the description of dementia praecox by Kraepelin (1913) it is
recognised that cognitive deﬁcits are an important aspect of schizo-
phrenia (Owens and Johnston, 1980; Saykin et al., 1991). In a sizeable
proportion of patients these deﬁcits contribute to progressive and sig-
niﬁcant intellectual impairment (McKenna et al., 1990; McGlashan
and Fenton, 1993), which in turn is an important predictor of functional
outcome (Green, 1997; Michalopoulou et al., 2013). Cognitive impair-
ment affects several neuropsychological domains: short- and long-
term memory, attention and executive functions (Saykin et al., 1991).
The ‘amnesic syndrome’ in schizophrenia or ‘schizophrenia dementia’
is characterised by disproportionate long-term memory impairment
(McKenna et al., 1990; Tamlyn et al., 1992).
The aetiology of cognitive impairment in schizophrenia is currently
not understood. It does not involve neuropathology characteristic forFig. 1. Loss of dendritic spines in supra-granular layers of superior temporal gyrus and in fronta
Micrographs of pyramidal cells in the cerebral cortex stained with the Golgi method. (A) A la
(B) Smooth, spineless segment on an apical dendrite in schizophrenic cortex. (C) A higher pow
(B) 15 μm and (C) 10 μm.
Reproduced with permission from: Garey LJ, Ong WY, Patel TS, Kanani M, Mortimer AM, Barne
neurons in schizophrenia. Journal Neurology Neurosurgery Psychiatry; 65: 446–453. See also Ga
neurodevelopmental disease of microcircuits. J.Anat., 217, 324–333.Alzheimer's disease (Purohit et al., 1998). The role of NMDA receptor
dysfunction had been suggested on the basis of cognitive effects of
NMDA receptor antagonists (Javitt and Zukin, 1991). Two key neuro-
pathological ﬁndings (obtained at Charing Cross Hospital in London)
were the primary motivation for our laboratory to begin exploring
MMN as an in vivo biological marker of cognitive impairment (Hirsch
et al., 1997). Garey et al. (1998) showed a distinct loss of dendritic
spines in the superior temporal cortex (and in a smaller series also in
frontal cortex) of post-mortem specimens obtained from patients with
schizophrenia (Fig. 1). This loss was most pronounced in layer III pyra-
midal neurons in supragranular layers which receive the majority of
cortico-cortical connections. NMDA receptors are particularly abundant
in those dendritic spines, and a further study linked the loss of NMDA
receptors in the superior temporal region (speciﬁcally gene expression
for the NR1 subunit) directly to the degree of cognitive impairment
which was determined prospectively (Humphries et al., 1996).
We expected that MMN could be a suitable in vivo biomarker for
such dysfunction, given its main generator site in the superior temporal
gyrus and its dependence on NMDA receptor mediated transmission, as
shown in bothmonkeys and humans (Javitt et al., 1996; Umbricht et al.,
2000).We predicted that impairment in MMN generation should be re-
lated to the degree of cognitive dysfunction in schizophrenia patients,
independently of the severity of current psychotic symptoms.l cortex in a patient with schizophrenia in comparison with age-matched healthy control.
yer III pyramidal cell from a control brain, showing its morphology and spiny dendrites.
er view of spines on an apical dendrite of a control pyramidal neuron. Scale: (A) 25 μm;
s TRE, Hirsch SR. (1998). Reduced dendritic spine density on cerebral cortical pyramidal
rey, L. (2010). When cortical development goes wrong: schizophrenia as a
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than is possible with the classical oddball protocol, we introduced the
roving stimulus protocol (Cowan et al., 1993) into a clinical context.
The continuously changing (‘roving’) sound input required the de
novo formation of echoic memory traces and by varying the number
of standard repetitions before each deviant, it was possible to probe
the efﬁcacy of echoic memory trace formation (memory trace effect).
Intuitively, this memory trace effect was intended to measure the ca-
pacity for encoding novel information, i.e. to probe short-term plasticity
processes. It was predicted that the degree of memory dysfunction
would be proportional to the efﬁcacy of encoding new auditory infor-
mation, i.e. equivalent to a diminution of theMMNmemory trace effect.
The data from a ﬁrst pilot study (Baldeweg et al., 2004) supported
this hypothesis, showing a diminution of theMMNmemory trace effect
(expressed as the relative increase or slope of MMN amplitude with
number of standards) in proportion to the impairment in working
memory, assessed neuropsychologically using digit span, and long-
term episodic memory, tested using the Rivermead Behavioural Memo-
ry Test. MMNwas negatively correlated with age and duration of illness
in patients, but no correlations were found between psychometric
scores, age and MMN in controls.1.3. Further support for the correlation of MMN with cognitive status
Näätänen et al. (2011, 2012) comprehensively reviewed MMN
studies which addressed this issue in patients with schizophrenia. In
brief, supportive evidence was also found for a predictive relation-
ship of MMN with global everyday functioning and independence of
community-living (Light and Braff, 2005), which is closely correlated
with cognitive status. Other studies also reported MMN–cognition cor-
relations (Kawakubo et al., 2006; Kiang et al., 2007; Toyomaki et al.,
2008; Turetsky et al., 2009). In addition, MMN was found correlated
with indices of social cognition and functioning (Kawakubo and Kasai,
2006; Wynn et al., 2010; Rasser et al., 2011).
More recently it was shown that MMN correlated with verbal ﬂuen-
cy scores in at-risk individuals (Higuchi et al., 2013) and with working
memory performance in the early phase of the illness (Miyanishi
et al., 2013), while theMMN–workingmemory correlation also extend-
ed to siblings of schizophrenia patients (Sevik et al., 2011). Frontal
MMN reduction was also associated with executive dysfunction
(Toyomaki et al., 2008), verbal learning and working memory deﬁcits
(Kaur et al., 2011), psychomotor slowing and attentional dysfunction
(Hermens et al., 2010). While the evidence for a MMN–cognitive status
correlation in schizophrenia reviewed above appears well replicated,
the question of its speciﬁcity to this disorder has not been addressed.Table 1
Demographic and clinical characteristics of study groups.
Controls Sch
N 49 49
Gender (male/female) 25/24 28
Age (years) 36.4 (11.5) 38
Handedness (L/R) 3/46 4/4
Parental SES (% in Social Classes I–III) 77.3% 58
Education (years) 11.9 (2.4) 10
Employed (%) 79.6% 22
Marital status (% married) 59.3% 18
NART IQ 112.4 (13.9) 11
Quick Test IQ 101.3 (12.6) 94
Age of onset (years) – 24
Duration of illness (years) – 10
Number of admissions – 4.4
PANSS positive – 19
PANSS negative – 17
PANSS general – 36
SES = socio-economic status, IQ = intelligence quotient, NART = National Adult Reading Tes
Signiﬁcant differences (p b 0.05) in planned comparisons: a — schizophrenia versus bipolar di1.4. The current study
It is important to note that similar MMN–cognitive status correla-
tions were also found in other conditions, such as intellectual disability,
healthy ageing and neurodegenerative diseases (reviewed in Näätänen
et al., 2011, 2012), which poses important questions about the speciﬁc-
ity of this relationship in schizophrenia. First, this relationship could be
due to non-speciﬁc factors, such as the presence of global brain atrophy,
a ﬁnding shared between major neuropsychiatric disorders and ageing.
Secondly, while previous studies have overwhelmingly shown that
MMN is intact in patients with bipolar disorder, these studies have
used the classical oddball paradigm (Catts et al., 1995; Umbricht et al.,
2003; Hall et al., 2007a, 2007b; Salisbury et al., 2007; Takei et al.,
2010). It is conceivable, that the stimulus encoding demands of the
roving stimulus paradigm poses a greater challenge in this population.
More complex stimulation protocols can reveal MMN deﬁcits which
the oddball paradigm fails to show (e.g. Kujala et al., 2006). Further-
more, more recent studies have reported MMN attenuation in bipolar
disorder cohorts (Andersson et al., 2008; Jahshan et al., 2012; Kaur
et al., 2012). Finally, none of the previous studies have probed the
MMN–cognition relationship in patientswith schizophrenia and bipolar
disorder in comparison with non-psychotic patients with cognitive
impairments (e.g. Alzheimer's disease) using the same experimental
setup.
Thus, the aims of the present study were: a) to replicate the ﬁndings
made using the roving stimulus protocol in a larger patient and control
sample; b) to compare the roving stimulus MMN between patients
with schizophrenia and bipolar disorder; and c) to test the speciﬁcity
of MMN–cognition correlation by comparison with patients with
Alzheimer's disease. The methodology was kept similar to that used
previously (Baldeweg et al., 2002, 2004); hence the description here
will be kept brief.
2. Methods
2.1. Participants (see Table 1)
Only patients satisfying the DSM-IV criteria for the respective diag-
noses were included in the study. Schizophrenia and bipolar disorder
(BD) patients were recruited from in- and out-patient clinics at the Psy-
chiatry Department, Charing Cross Hospital, while Alzheimer's disease
(AD) patients were recruited from the Neurology Department, Charing
Cross Hospital, and the Old Age Psychiatry Department, St Charles
Hospital, all in London, UK. Exclusion criteria were a history of head in-
jury, hearing loss, epilepsy, electro-convulsive therapy in the last
3 years, or recent drug and alcohol abuses. The study was approved byizophrenia Bipolar disorder Alzheimer's disease
25 15
/21 12/13 9/6
.0 (12.5) 38.1 (10.3) 71.2 (11.9)b
5 3/22 1/14
.3% 65.4% 69.2%
.7 (2.2) 11.6 (2.4) 10.1 (2.4)
.4%a 46.2% –
.3% 26.9% 65.3%
0.2 (8.9) 101.4 (9.28) 108.0 (6.8)
.1 (12.6) 100.0 (10.1) –
.4 (6.5) 29.3 (7.3)a 68.1 (10.2)
.4 (9.1) 8.8 (7.5) 3.1 (1.3)
(4.4) 3.7 (2.7) –
.3 (6.3) 17.3 (5.1) –
.1 (5.3) 13.5 (3.4)a –
.4 (8.0) 33.3 (6.1) –
t, PANSS = Positive and Negative Syndrome Scale.
sorder and b — schizophrenia compared to Alzheimer's disease.
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Ethics Committee London, UK.
2.1.1. Schizophrenia patients (n = 49)
Patients with a DSM-IV diagnosis of schizoaffective disorder were
excluded. All but one patient were taking neuroleptic medication. Of
these, 39 (80%) were prescribed atypical anti-psychotic medications.
Other medication included antidepressants (15 patients), lithium (9
patients), anticonvulsant mood stabilisers (10 patients) and anti-
parkinsonian agents (9 patients). The average chlorpromazine equiva-
lent was 337 mg/day (SD 351).
2.1.2. Control participants (n = 49)
Healthy control participants were recruited by local advertisements.
Exclusion criteriawere a history of neurological or psychiatric problems,
hearing loss, drug or alcohol abuse, or a ﬁrst-degree family member
with a psychiatric disorder.
2.1.3. Bipolar disorder (BD) patients (n = 25)
Among the patients with bipolar disorder, 11 (48%)were on atypical
anti-psychotic medications. Mood stabilisers were prescribed to 15, an-
tidepressants to 8, and anti-parkinsonian agents to 1. A positive history
of psychosis (hallucinations and/or delusions)was reported in 14 (56%).
2.1.4. Alzheimer's disease (AD) patients (n = 15)
Patients with a history of vascular disease were excluded. Due to
practical difﬁculties three Alzheimer's disease patients were unable to
undergo full neuropsychological assessment.
2.2. Procedures
2.2.1. Psychiatric assessment
All patients were assessed by a qualiﬁed psychiatrist using clinical
interview and the severity of current symptoms was assessed using
the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987).
2.2.2. Neuropsychological evaluation
Patients were screened for impairment in everyday memory using
the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and
the Rivermead Behavioural Memory Test (RBMT) (Wilson et al.,
1985), a test of memory domains relevant to everyday functioning.
Working memory was tested using the WAIS-R Digit Span Forward
and Backward (Wechsler, 1981). Executive control and semantic
retrieval were assessed using the verbal ﬂuency FAS score from the
Controlled Oral Word Association Test (Benton and Hamsher, 1976).
Pre-morbid verbal intelligence was assessed using the National Adult
Reading Test (NART) (Nelson, 1982), while current intellectual func-
tioning was estimated using the Quick Test (QT) (Ammons and
Ammons, 1962). Handedness was determined using the Annett Scale
(Annett, 1972).
2.2.3. ERP acquisition
EEGwas recorded continuously from30 electrodes and left and right
mastoids (M1,M2) placed according to the international 10–20 system.
Silver/silver chloride electrodes were attached using self-adhesive
paste. The vertical electro-oculogram was recorded from electrodes
placed above the right eye and the right outer canthus. System band
passwas 0.1–30Hz, with a digital sampling rate of 500Hz and reference
was placed on the bridge of the nose. The subjects were seated in a con-
formable chair in an acoustically shielded room and watched a silent
and subtitled video. Relative hearing levels were tested binaurally
using a staircase procedure at 800 and 1000 Hz before EEG recording
commenced. None of the participants exhibited hearing problems.2.2.4. Stimulation
A roving stimulus paradigm with duration and frequency deviants
was used with slight modiﬁcations from that used previously
(Baldeweg et al., 2002, 2004). Pure sinusoidal tones (80 dB SPL, 5 ms
rise/fall) were delivered binaurally via headphones. A stimulus train
consisted of a sequence of standard tones of one constant frequency
and duration (25 ms) and which were followed by a deviant tone of
the same pitch but differing in tone length (75 ms, duration deviant).
Each train was followed by a new train of stimuli with a different fre-
quency. The ﬁrst stimulus of the new stimulus train therefore served
as a frequency deviant for the preceding train (minimum frequency
separation 50 Hz). Twelve different frequencies from 700 Hz to 1250
Hz were used. The number of standards in each stimulus train was ei-
ther 2, 6 or 36, varied randomly from one train to the next (stimulus
onset asynchrony 300 ms, inter-train interval 300 ms, total of 3194
stimuli, including 645 deviants). In modiﬁcation to the original para-
digm a random number of standards (ranging randomly from 1 to 4)
after each duration deviantwere inserted, so that duration and frequen-
cy MMN could be measured independently, without baseline contami-
nation by the preceding duration deviant-elicited P3a.2.2.5. ERP data processing
Data were ﬁltered off-line with a band pass of 0.1–15 Hz. EEG data
epochs were 400 ms long with a pre-stimulus baseline of 100 ms. All
epochswith amplitudes exceeding+/−100 μV in any of the derivations
were excluded automatically. MMN was measured in the difference
waves obtained by subtracting the ERP to the immediately preceding
standard from the deviant ERP. MeanMMN amplitude was determined
in the difference waveforms between 100 and 200ms post-stimulus for
frequency MMN, and between 120 and 220 ms for duration MMN.
MMN peak amplitude and latency will not be reported here, for brevity.
To investigate the efﬁcacy of auditory sensory memory encoding
(memory trace effect), the increase of MMN amplitude with increasing
standard repetition (MMN slope) was calculated for duration and
frequency MMN amplitudes. This was done by subtracting MMN to de-
viants presented after n= 2 repetitions fromMMN amplitudes to devi-
ants presented after n= 36 repetitions (Baldeweg et al., 2004; Schmidt
et al., 2012).2.3. Statistical analysis
Group differences in demographic, clinical and cognitive data were
tested using independent sample t-tests, analysis of variance and χ2 or
Fisher's exact tests, where appropriate. Group differences in neuropsy-
chological scores were ﬁrst evaluated usingmultivariate analysis of var-
iance (MANOVA) with task as within-subject factor and group as
between-subject factor.MMNamplitudeswere analysed using repeated
measures analysis of variance (RMANOVA)withMMN type (frequency,
duration), standard repetition (n=2, 6, 36) and electrode (Fz, F3, F4) as
within-subject factors, and group as between-subject factor. Least
square difference test was done for post-hoc analysis. Non-parametric
correlations were computed between neuropsychological test scores
and MMN amplitudes using Spearman's rank correlation. A two-tailed
p value less than 0.05 was considered signiﬁcant throughout. Linear re-
gression analysis was used to determine neuropsychological correlates
of MMN impairment with model selection performed in a stepwise
fashion using the R2 change statistic.3. Results
We ﬁrst investigated MMN differences between schizophrenia and
bipolar disorder (BD) groups, before investigating the memory trace ef-
fect in relation to cognitive status in both schizophrenia and AD groups.
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3.1.1. Comparison of schizophrenia and bipolar disorder (BD) groups
The groups did not differ in age, gender, parental socio-economic
status, pre-morbid IQ (NART) and time spent in education (Table 1).
Both patient groups did not differ in duration of illness and number of
hospital admissions, but patients with bipolar disorder were older at ill-
ness onset. Of note is that the two clinical groups did not differ in their
positive or general psychopathology (PANSS) scores, while schizophre-
nia patients had higher negative PANSS scores, compatible with reports
from other cohorts (Rosen et al., 2012).
3.1.2. Comparison of schizophrenia and Alzheimer's disease (AD) groups
The Alzheimer's disease group was older than controls and schizo-
phrenia patients (F(df = 3,127) = 32.9, p b 0.05) but did not differ in
gender ratio and parental socioeconomic status. While premorbid IQ
and education was not different between patient groups (Table 1), the
AD group was considerably more cognitively impaired (mean Mini-
Mental State Examination (MMSE) score: 20.3 SD 1.8) than the schizo-
phrenia group (MMSE score: 28.4 SD 1.8) and many AD patients were
not able to complete the RBMT test (not reported here).
3.2. MMN comparison of schizophrenia and bipolar disorder groups
Systematic comparison of effect sizes across studies has established
that the lowest deviant probability results in the greatest likelihood
of detecting signiﬁcant MMN group differences (Javitt et al., 1998;
Umbricht and Krljes, 2005). Thus in order tomaximise the chance of ob-
serving robust differences between psychosis groups we restricted the
comparisons to the longest (n = 36) standard repetition condition.
3.2.1. MMN comparison of schizophrenia and bipolar disorder groups
(Fig. 2)
AspredictedMMNamplitudewas severely reduced in the schizophre-
nia group compared to each other group but there was no difference be-
tween controls and BD patients (mean MMN (in μV) and standard
deviation for control, schizophrenia and BD groups, respectively —
duration MMN:−2.7 (1.4),−0.6 (1.2), and−2.5 (1.4) and frequency
MMN: −3.5 (1.5), −0.8 (1.5), and −3.3 (1.7)). This was conﬁrmed
using a repeated-measures ANOVAwith MMN type (duration, frequen-
cy) as within-subject factor and group (controls, schizophrenia, bipolar
disorder) as between-subject factor showing a group effect (F(df =
2,120) = 82.4, p b 0.05), but there was no signiﬁcant group by MMN
type interaction. Furthermore, post-hoc tests demonstrated that schizo-
phrenia patients differed from healthy controls and bipolar patients (all
p b 0.05), while no difference was observed between bipolar group and
healthy controls (all p N 0.05). The group differences reported for
both deviants combined were also signiﬁcant for each of them: dura-
tion deviant: F(df= 2,120)= 42.47, p b 0.05 and frequency deviant:Fig. 2.MMNgroup comparison shows impairment in the schizophrenia but not in the bipolar dis
MMN recorded after n = 36 standard repetitions.F(df = 2,120) = 51.09, p b 0.05, with post-hoc differences (all p
b 0.05) between schizophrenia and controls and schizophrenia and
BD groups but no difference for BD and controls, for both deviant
types tested separately. The group differences persisted after includ-
ing negative PANSS scores as covariate of no interest.
Furthermore, MMN was compared between patients with bipolar
disorder who had a positive history of psychosis (N = 14) and those
who did not (N= 11). No signiﬁcant differencewas observed for either
duration MMN (t = 1.40, df = 23, p N 0.05) or frequency MMN (t =
0.21, df = 23, p N 0.05). Finally, MMN in the bipolar disorder group
was not affected by the use of mood stabilising medication and there
were no correlations with PANSS symptom scores (all p N 0.168).
In summary, although both patient samples reported a similar level
of positive psychotic symptoms at the time of testing, robust MMN def-
icits were observed only in patients with schizophrenia.
3.3. MMN memory trace effect in schizophrenia and Alzheimer's disease
groups
Next, we examined the relationship of MMN to cognitive functions
in patients with schizophrenia and subsequently tested if this relation-
ship is similar to that of AD patients.
3.3.1. Neuropsychological evaluation and deﬁnition of schizophrenia
cognition groups
The schizophrenia group was impaired relative to controls across
all neuropsychological test scores (MANOVA effect of group: F(df =
1,97) = 96.5, p b 0.05). However, the impairment was not uniform as
suggested by group by test interaction (F(df = 5,92) = 11.7, p b 0.05).
For comparison of the different tests, the neuropsychological scores of
the schizophrenia group were expressed as z-scores derived from the
scores of the control group. The largest impairments were evident in
long-term memory (RMBT, z = −2.9) and working memory (Digit
Span Forward, z = −2.1), with least (non-signiﬁcant) deﬁcits
in premorbid IQ (NART, z = −0.5). Since the variability in cognitive
function was large, the patient sample was divided (using a median
split at z = −1.44 on the overall performance z score) into a higher
cognition group (N = 23, mean z =−0.9) and lower cognition group
(N = 26, mean z =−2.1). The two cognition groups did not differ in
most of their demographic and clinical characteristics (see Supplemen-
tary Table); however the lower cognition group was less likely to be
employed (χ2 (N = 49, df = 1) = 10.80, p b 0.05) and married (χ2
(N = 49, df = 3) = 65.5, p b 0.05) than the higher cognition group.
3.3.2. MMN memory trace effect in patients with schizophrenia and
Alzheimer's disease
Further to the MMN reduction for the largest number of repetitions
reported above (Fig. 2), we ﬁrst compared the memory trace effect
between the schizophrenia and control groups. As predicted MMNorder group in comparisonwith healthy controls. This is shown for duration and frequency
Fig. 3.Groupmeans of theMMNmemory trace effect show impairment in schizophrenia but not in patients with Alzheimer's disease in comparisonwith healthy controls (A). Please note
that the amplitude scale was altered for the grandmean of the schizophrenia group (*) to visualise the attenuation of this effect more clearly. (B) Mean duration MMN amplitudes across
groups, including thehigher and lower cognition schizophrenia groups, showingpreservation ofMMNmemory trace effectwith repetition in thehigher cognition group but this effectwas
abolished in the lower cognition group. An identical effect is seen for the frequency MMN (data not shown here).
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fectwasmarkedly attenuated in the schizophrenia group (groupby rep-
etition effect: F(df = 2,95) = 17.5, p b 0.05). Please note that the
amplitude scale in Fig. 3A was altered for the grand mean of the schizo-
phrenia group to visualise the attenuation of this effect more clearly.
Next we considered the MMN memory trace effect in AD patients
(Fig. 3A, right column). Somewhat surprisingly, there was no visible
MMN attenuation in the AD group which is supported by statistical
analysis. While the overall RMANOVA group (controls, schizophrenia,
AD) by repetition interaction effect was signiﬁcant (F(df = 4,216) =
8.8, p b 0.05), post-hoc test demonstrated that only schizophrenia
patients differed in their MMN responses from healthy controls
(all p b 0.05). The main effects of group (F(df = 2,108) = 71.34,
p b 0.05) and of repetition were also signiﬁcant (F(df = 2,107) =
17.34, p b 0.05). No overall MMN difference was observed between
Alzheimer's patients and healthy controls. MMN slopes of the
AD group were indistinguishable from control values for duration
(t =0.25, df = 50, p N 0.05) and frequency MMN (t = 0.78, df =
50, p N 0.05), while they were larger than those of the schizophrenia
group (duration: t = 2.56, df = 50, p b 0.05; frequency: t = 5.72, df =
50, p b 0.05).
In order to visualise the effect of cognitive statuswe plotted duration
MMN amplitude separately for the two schizophrenia cognition groups(shown in Fig. 3B). This graph demonstrates that the memory trace
effect was preserved in the higher cognition group, i.e. the slope of
MMN change was similar to that of controls, despite an overall reduc-
tion in MMN amplitude. In contrast, the lower cognition group did not
show any evidence for MMN increase with repetition.
Finally, a subgroup of 13 schizophrenia patients with the lowest
MMSE scores was selected to match the AD individuals on overall
cognitive status (MMSE score) and their MMN was compared to
the Alzheimer's group. ANOVA again showed a main effect of group
(F(df = 1,24) = 25.3, p b 0.05) and a group by repetition interaction
(F(df = 2,23) = 12.6, p b 0.05), conﬁrming the above ﬁndings from
the total sample to this subgroup analysis. The two groups also differed
in their MMN slopes (duration MMN: t = 3.32, df = 23, p b 0.05; fre-
quency MMN: t = 5.77, df = 32, p b 0.05).
3.3.3. Correlations of MMN slope with neuropsychology scores
In patients with schizophrenia, MMN slopes (at electrode Fz) were
correlated signiﬁcantly (all p b 0.05) with the following neuropsycho-
logical scores: frequency MMN: Digit Span Forward (r = −0.64),
RBMT total score (r = −0.37), and verbal ﬂuency FAS score (r =
−0.34) and duration MMN: Digit Span Forward (r = −0.43), RBMT
(r =−0.63), and verbal ﬂuency (r =−0.35). There were no correla-
tions with PANSS symptom scores. Stepwise linear regression
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MMN were Digit Span Forward (b = −0.47) and RBMT scores (b =
−0.38). For duration MMN the only signiﬁcant predictor was RBMT
score (b =−0.43). There were no signiﬁcant correlations between
MMN slopes or amplitudes and psychometric scores of the BD and AD
groups (all r b 0.28, all p N 0.168).
4. Discussion
This is theﬁrst study to evaluate the diagnostic speciﬁcity ofMMN in
comparison with bipolar disorder and Alzheimer's disease, to address
the important question of its correlation with cognitive status. The cur-
rent study yielded a number of key ﬁndings. First, we replicate the cor-
relation of the memory trace effect with neuropsychological memory
scores in patients with schizophrenia in a larger sample of participants.
Secondly, we show that this correlation was not observed in patients
with bipolar disorder, who shared a comparable level of positive symp-
toms and general psychopathology. Finally, we show that patients with
Alzheimer's disease, who demonstrated more severe cognitive impair-
ment than schizophrenia patients, showed preserved MMN. Overall,
this argues for a striking degree of speciﬁcity of MMN for the cognitive
impairment associated with schizophrenia.
4.1. MMN and cognition across aetiological groups
In agreement with our pilot study, we found that MMN slope corre-
lated most consistently with working and episodic memory scores.
MMN therefore appears sensitive to deﬁcits in encoding sensory infor-
mation and this predicted patients' inability to store information in
bothworkingmemory and long-term episodicmemory, but is not relat-
ed to their premorbid ‘crystallised’ intelligence. This suggests that the
cortical dysfunction indexed by MMN is replicated in higher-order cor-
tical networks, as sensory memory, working memory and episodic
memory systems are neuropsychologically dissociable, i.e. are support-
ed by distinct cortical networks. Auditory sensory memory is localised
in the superior temporal cortex (Colombo et al., 1990) and working
memory supported by fronto-parietal regions, while episodic memory
is mainly dependent on hippocampal circuitry (Mishkin et al., 1998).
This is in stark contrast to AD patients, who showed preservedMMN
despite exhibiting more severe memory impairments, presumably
caused by themedial temporal emphasis of Alzheimer's disease pathol-
ogy (Braak and Braak, 1995; Nelson et al., 2012). OurMMN ﬁndings are
compatible with data of Pekkonen et al. (1994) who reported normal
MMN in AD patients at short inter-stimulus intervals (1 s) but reduced
MMN at longer intervals of 3 s. Reduced MMN (during active oddball)
but preserved MMN to environmental sounds were reported by
Kazmerski et al. (1997) but Gaeta et al. (1999) reported normal MMN
to small and large frequency deviants in AD patients compared to elder-
ly controls. We conclude that MMN reﬂects a severe disruption to sen-
sory encoding in schizophrenia, while the reverse is the case in AD
where preserved encoding contrasts with accelerated memory trace
decay (Näätänen et al., 2011).
Given the overlap in clinical presentation and genetic inﬂuences
of BD and schizophrenia there is an ongoing debate of the role of shared
aetiological factors for the two major psychoses (Goldberg et al., 2009).
The role of glutamatergic dysfunction in BD is under investigation using
magnetic resonance spectroscopy andMMNwith evidence for amoder-
ate reduction in glutamate metabolites and MMN magnitude (Chitty
et al., 2013). It is not yet known if ﬂuctuating mood status accounts
for some of the diverging ﬁndings (Kaur et al., 2012; Chitty et al.,
2013). We observed that MMN clearly differed between schizophrenia
and BD groups even though they were matched for some important
characteristics of their psychopathology (positive and general PANSS
scores). However, it is conceivable that the MMN difference is due to
differences in cognitive functioning between groups. Our data do not
suggest that this is the case. Patients with bipolar disorder performedsigniﬁcantly worse than the control group on a number of tests (data
not shown) and the average neuropsychological z score indicated a
general cognitive deﬁcit of 1.4 standard deviations below the healthy
control mean. This ﬁnding is in line with evidence that BD patients
can show a similar proﬁle of neuropsychological impairment, that is
however less severe than in patients with schizophrenia (Vohringer
et al., 2013). Furthermore, this score was signiﬁcantly lower than
of the higher cognition schizophrenia group (z = −0.9) (t =
2.56, p b 0.05); nevertheless their MMN was signiﬁcantly larger
than in the higher cognition group (group effect across all deviants:
F(df = 1,46) = 27.8, p b 0.05). Importantly also no correlations be-
tween MMN and any of the psychometric scores were found for this
group.
The discrepancy in MMN ﬁndings across studies of affective spec-
trum disorders (with some studies reporting MMN reduction while
others do not) remains to be resolved,with a suggestion that differences
between diagnostic groups are less pronounced in the early phase of the
illness (Kaur et al., 2012) an issue that can only be resolved in longitudi-
nal studies (Kaur et al., 2013).
Thus, we conclude that, much like the comparison with AD patients,
the MMN difference between bipolar disorder and schizophrenia
groups was not due to a difference in cognitive status. This apparent
speciﬁcity of MMN to cognition in schizophrenia is complementary to
the notion that the oddball MMN indexes a subtle decline across ageing
(e.g. Kiang et al., 2009) and in neurodegenerative disorders (Näätänen
et al., 2011). Given the limited age range of this study, we did not ﬁnd
robust MMN correlations with age in any group. MMN correlated
inversely with duration of illness in the schizophrenia group only, as
commonly reported (Umbricht and Krljes, 2005). We suggest that the
combination of rapid and constantly changing stimulus input of the rov-
ing paradigm exposed a particular weakness of the auditory system in
schizophrenia that exceeds the MMN sensitivity to overall cognitive
decline. However, a comparison of the roving stimulus protocol with
the classical oddball paradigm (e.g. Cooper et al., 2013) is needed to
test this hypothesis.
4.2. Methodological considerations
It is important to acknowledge the limitations of this study. First, our
study was not designed to demonstrate MMN and cognitive impair-
ment in bipolar disorder. The effect size of MMN reduction was 0.14
and of a similar magnitude to that reported by Umbricht et al. (2003).
We would have required a sample of several hundred participants per
group to conﬁrm a difference with sufﬁcient statistical power. Data
from the largest bipolar disorder sample reported so far (Hall et al.,
2007a, 2007b) are in agreement with our ﬁndings which are in stark
contrast to the large effect sizes commonly achieved when comparing
schizophrenia groups with controls (Umbricht and Krljes, 2005).
The same limitation also applies to our comparisonwith Alzheimer's
disease, in addition to our failure to recruit an older age-matched con-
trol group. Only a small number of eligible Alzheimer's disease patients
could be included into this study, as over half of potential participants
had a history of vascular disease. Other eligible patients were too im-
paired to cope with the testing schedule. Nevertheless, despite the larg-
er cognitive compromise in this group (ranging from mild dysfunction
in those with short duration of illness to severe dementia), the MMN
ﬁndings are robustly showing intact auditory stimulus encoding at
short inter-stimulus intervals, in overall agreement with literature ﬁnd-
ings. While we cannot rule out the possibility of MMN impairment in
both bipolar disorder and Alzheimer's disease groups, we can ﬁrmly
conclude that using the stimulation parameters of our study it appears
of a qualitatively differentmagnitude to that observed in schizophrenia.
We admit that the division of the schizophrenia sample into two
cognition groups is somewhat arbitrary and here only served to visual-
ise the different proﬁles of MMN memory trace effects (Fig. 3B). It also
usefully demonstrates that cognitive status is distinct from positive
152 T. Baldeweg, S.R. Hirsch / International Journal of Psychophysiology 95 (2015) 145–155symptoms of schizophrenia, as the cognition groups only differed in
negative symptom scores and marital and employment status. This is
in agreementwith the robust association reported forMMNwith gener-
al functioning (Light and Braff, 2005) with recent evidence showing a
closer relationship to independence of living andwork than social func-
tioning (Wynn et al., 2010).
Amajor caveat is that themajority of patientswere using psychotro-
pic medication. In line with others (Jahshan et al., 2012; Kaur et al.,
2012) we did not ﬁnd direct evidence that mood stabilisers and neuro-
leptic medication affected MMN, but caution is due when interpreting
this data.
Finally, this study was also not designed to address the nature of
MMN impairment in schizophrenia (see Todd et al. (2012) for a detailed
discussion), such as the contribution of lower precision of sound repre-
sentation and increased discrimination thresholds (Javitt et al., 1997;
Todd et al., 2003). First, it is worth noting that in our previous study
which also failed to show frontal MMN responses in the patient group,
basic tone frequency discrimination (tested behaviourally before
MMN recording) was relatively intact when tested on frequency chang-
es which were used during MMN recording. This ﬁnding supports the
study by Todd et al. (2003) who reported MMN reduction in schizo-
phrenia patients with intact discrimination thresholds. This conclusion
is also supported by the relative preservation of the mastoid mismatch
positivity in previous studies (Sato et al., 2003; Todd et al., 2003;
Baldeweg et al., 2004), which was conﬁrmed at the group level in the
present study (data not shown, but see Fig. 2, right), suggesting that
some element of sensory discrimination was intact.
Second, the adoption of the roving stimulus paradigmwas intended
to capture a neurophysiological signature of sound encoding deﬁcits in
schizophrenia. The putative ERP correlate, the repetition positivity
(RP), was indeed found reduced in schizophrenia patients (Baldeweg
et al., 2004), independently from the reduction in deviant negativity.
While there is evidence that experimental manipulations (repetition,
attention, timing regularity) which inﬂuence the strength of sensory
memory also modulate RP (Haenschel et al., 2005; Costa-Faidella
et al., 2011), a direct correlation with behavioural sensory discrimina-
tion performance has not yet been reported. Nevertheless, we conﬁrm
that patients who demonstrated a profound impairment in thememory
trace effect (and by inference be impaired in sensorymemory tasks) are
also impaired in working and long-termmemory tasks. Such presumed
correlation between sensory precision and higher order cognition is
made even more likely as the behavioural estimation of perceptual
thresholds in turn is critically inﬂuenced by cognitive factors such as
motivation, attention and intellectual abilities (e.g. Amitay et al., 2010).4.3. Models of auditory short-term plasticity
After having documented the sensitivity of MMN to cognition in
schizophrenia we now wish to review some of the progress made in
uncovering putative mechanisms underlying these deﬁcits. There is
compelling evidence for the role of NMDA receptor blockade in MMN
generation in monkey (Javitt et al., 1996), rodent (Ehrlichman et al.,
2008) and human studies (Umbricht et al., 2000; Kreitschmann-
Andermahr et al., 2001; Heekeren et al., 2008). However, it is not
known if the MMN memory trace effect as employed in our studies is
also sensitive to NMDA receptor blockade. This was investigated by
Schmidt et al. (2012) using the roving stimulus paradigm of Garrido
et al. (2008). They showed that s-ketamine, which blocks NMDA recep-
tors, but not psilocybin, a 5-HT2A receptor blocker, reduces the MMN
memory trace effect, expressed as the slope of MMN amplitude over in-
creasing numbers of standard repetitions. Although both drugs induced
similar levels of positive psychosis-like symptoms in healthy volunteers,
MMN slope during the placebo condition predicted perceived cognitive
deﬁcits induced by ketamine only, conﬁrming the ﬁndings of Umbricht
et al. (2002) obtained using the classical oddball MMN.Furthermore, this group explored using dynamic causalmodelling of
scalp ERP the relative contribution of two putativemechanisms ofMMN
generation (adaptation vs. model adjustment) to the observed drug ef-
fects (Schmidt et al., 2013). Garrido et al. (2008, 2009) had previously
introduced dynamic causal modelling for inferring causal relationships
between neural generators of MMN. Adaptation of tonotopically
organised auditory neurons (May et al., 1999) wasmodelled as changes
in intrinsic connections of auditory cortex dipole generators (local gain
control). The model adjustment hypothesis (Winkler et al., 1996) was
implemented by examining short-term plasticity in long-range (extrin-
sic) connections between generators in primary and secondary auditory
cortex. Schmidt et al. (2013) were able to replicate the ﬁndings of
Garrido et al. (2009) by showing that both intrinsic auditory cortex ad-
aptation and short-term plasticity in extrinsic connections between
sources are required to explain MMN generation. Ketamine reduced es-
timates of synaptic plasticity but not of adaptation, and the former effect
was correlated with ratings of ketamine-induced impairments of cogni-
tion. These ﬁndings are in complete agreement with another (yet un-
published) study employing the same roving paradigm as used in the
present study (see Baldeweg (2007) for further information). This
lends overall support for the initial intuition that the MMN memory
trace effect at least partially expresses NMDA receptor-dependent corti-
cal plasticity. Pharmacological challenge studies also support the link to
cognitive impairment by showing that ketamine (but not other halluci-
nogens) induces impairments in both MMN and cognition (Umbricht
et al., 2000; Heekeren et al., 2008; Schmidt et al., 2012).4.4. Convergence of neuropathology and mismatch generation: prediction
error detectors in supragranular cortex (Fig. 4)
Our original motivation for exploring theMMN as an in vivo marker
of cognitive dysfunction was based on the discovery of synaptic pathol-
ogy in supragranular neurons in the brains of patients with schizophre-
nia (Garey et al., 1998; Humphries et al., 1996; Glantz and Lewis, 2000).
We now revisit this ﬁnding within the context of recent evidence from
neurophysiology and computational neuroscience.
On the basis of the surprising observation that the MMN recorded
using the roving paradigm could be completely explained by repetition
effects to the standards (‘repetition positivity’, see Haenschel et al.,
2005; Costa-Faidella et al., 2011), we invoked a novel theory of percep-
tual learning proposed by Friston (2003, 2005a) to account for the neu-
rophysiological responses (Baldeweg et al., 2004, 2006). In short, during
perceptual learning, hierarchical sensory systems employ ‘predictive
coding’, where each level of the hierarchy receives bottom-up predic-
tion errors from the level below and top-down predictions from the
level above. At the lowest sensory level, this prediction error is simply
the sensory input that has yet to be predicted. Deviation from the
predicted sensory input (deviant) elicits error signals in lower levels
(expressed physiologically asmismatch responses or prediction errors),
which are propagated up the sensory hierarchy to inform higher level
representations to elaborate top-down predictions. During stimulus
repetition, connection strengths between hierarchical levels are adjust-
ed, through synaptic plasticity, to suppress prediction error more efﬁ-
ciently. The physiological correlate of this is repetition suppression
(i.e. repetition positivity). The roving stimulus paradigm is ideally suited
to elicit robust ERP correlates of this process because prediction error
generation and suppression are repeated with each new (roving)
stimulus train. This model has been well supported by experimental
data (reviewed in Baldeweg (2007) for MMN — and see Bastos et al.
(2012) for a comprehensive review of the microcircuitry underlying
predictive coding). We speculated that MMN generation and its deﬁcit
in schizophrenia could be understood within the framework of predic-
tive coding (Baldeweg et al., 2004, 2006; Baldeweg, 2006, 2007;
Stephan et al., 2006; see also Todd et al. (2012) for a consideration of
the nature of prediction error deﬁcit). In brief, there is remarkable
Fig. 4. Schematic showing the convergence of synaptic neuropathology (A: loss of NMDA receptor containing spines on layer III pyramidal cells (shown inwhite box and photomicrograph
from Garey et al., 1998) with B: the intracortical locus of MMN generation (adapted from the ﬁndings of Javitt et al., 1996). Deviant-elicited potentials (red, MMN) are mainly recorded
from supragranular layer II/III, where NMDA receptor blockers can suppress them without affecting input into layer IV. C: Supra-granular neurons play a strategic computational role
as prediction error-unitswithin hierarchical cortical networks that employ predictive coding (Friston, 2005a). These error-units are the source of forward (bottom-up) connectionswithin
the brain (shown in red) conveying prediction error to higher levels. Top-down predictive signals are relayed via backward projections (shown in black) from higher-level infra-granular
layers to lower-level supra-granular pyramidal cells. Critical details of the intrinsic (lateral) cortical connections including inhibitory interneurons are omitted here (see Friston andKiebel,
2009; Bastos et al., 2012 for details).
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legend for further explanations):
First, the cytoarchitectural features of schizophrenia – as reviewed
by Harrison (1999) – comprise of reduction of synaptic connectivity,
predominantly affecting dendritic inputs to layer II/III pyramidal
cells. This layer- and disease-speciﬁc arrangement has been docu-
mented for the hippocampus (Harrison and Eastwood, 1998),
dorso-lateral frontal neocortex (Garey et al., 1998; Glantz and
Lewis, 2000; Kolluri et al., 2005) and temporal neocortex (Garey
et al., 1998). Many schizophrenia risk genes converge on the physi-
ology of these NMDA receptor-containing synapses (Harrison and
Weinberger, 2005).
Second, supra-granular cortical layers are the main source of mis-
match responses — as determined from intracortical recordings
(Javitt et al., 1996). Critically, NMDA receptor blockade abolished
MMN in layer II/III but did not affect afferent thalamic input into
layer IV.
Third, theoretical accounts of predictive coding in neocortical cir-
cuits suggest that the connectivity of layer II/III pyramidal neurons
endows themwith a strategic role to select the most likely interpre-
tation of inputs (Douglas andMartin, 2004). More, speciﬁcally, layer
II/III pyramidal cells have been postulated to act as error-detectors
under predictive coding models of perception (Mumford, 1992;
Friston, 2005a). In a more recent formulation (Bastos et al., 2012)
these cells (jointly with local interneurons) encode and propagate
prediction error forwards to higher cortical levels.
The concordance between the major locus of neuropathological
changes in schizophrenia (Harrison, 1999; Garey, 2010) and the
intracortical site of MMN generation could account for the remarkable
robustness of MMN deﬁcits in this disorder. Furthermore, it explains
why the MMN indexes the degree of cognitive impairment because
the speciﬁc synaptic pathology in superior temporal cortex (subservingMMN, sensory memory) is replicated in lateral frontal cortex (e.g.
subserving working memory, executive functions) and hippocampus
(episodicmemory) as reviewed above. This is also supported by the cor-
relation ofMMNdeﬁcits with greymatter density reductions not only in
the superior temporal cortex (Salisbury et al., 2007) but also in frontal
cortex (Rasser et al., 2011).
The consilience of predictive coding and pathophysiology in schizo-
phrenia provides an elegant framework to explain how a relatively
subtle synaptic pathology (but situated in a critical hub) can have
profound effects across cortical hierarchies, giving rise to pervasive
impairments — from perception to higher-order cognition. Further-
more, abnormal prediction error processing has been implicated in psy-
chosis more widely (Stephan et al., 2009) to account for hallucinations
(Friston, 2005b) as well as delusions through impaired speciﬁcation of
prior expectations and aberrant signalling of their violations (Corlett
et al., 2007, 2011; Adams et al., 2013).
5. Conclusions and implications
We reviewed the evidence that MMN deﬁcits are correlated with
cognitive impairment in patients with schizophrenia. We also present-
ed conﬁrmatory data using the roving stimulation protocol to show
that this correlation is reproducible and robust. In addition, we found
no evidence for MMN–cognition correlations in patients with bipolar
disorder and Alzheimer's disease, which suggests illness-speciﬁc dis-
ruption of MMN networks in schizophrenia. These ﬁndings require rep-
lication and clariﬁcation, for example, if they are dependent on the
speciﬁc stimulation parameters used here to elicit MMN. If conﬁrmed,
they will inform the debate on the aetiological overlap of schizophrenia
and bipolar disorder (Goldberg et al., 2009).
Our ﬁndings add to the growing literature suggesting that MMN
can be used not only for identiﬁcation of at-risk individuals (Baker
et al., 2005; Bodatsch et al., 2011) but importantly also for thepreclinical
evaluation of novel therapeutic agents (Korostenskaja and Kahkonen,
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schizophrenia to MMN ﬁndings over the last 20 years has provided a
clear rationale for the development of NMDA receptor agonists (Javitt
et al., 2012) with clinical trials now under way (e.g. Umbricht et al.,
2010; Harvey and Yee, 2013). Based on our own experience
we suggests that MMN recorded using the roving stimulus paradigm
can serve as a sensitive translational biomarker to evaluate neuro-
pharmacological effects of cognition-enhancing agents in humans, for
example with reference to nicotine which exerts a positive effect on
MMN (Baldeweg et al., 2006) and ketamine with the opposing effect
(Schmidt et al., 2012).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijpsycho.2014.03.008.
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